UVM highlights R1 status, semiconductor hub, rural BioLabs and a tick‑borne disease vaccine effort

President Marlene Trump emphasized research and economic-development partnerships in testimony to the House of Communications Committee, citing UVM's recent R1 Carnegie classification and several applied projects that she said benefit Vermont’s workforce and health-care capacity.

Trump noted UVM’s R1 status as evidence of high research activity and cited specific initiatives: a gallium-nitride semiconductor hub operated in partnership with GlobalFoundries, $3,400,000 in funding reported from the Northeast Microelectronics Coalition, and a five-part federal grant proposal that the university has submitted and said could yield 'tens of millions of dollars.' She also said UVM hosts a rural BioLabs hub in Burlington to accelerate biotechnology commercialization across the region.

Vaccine research: Trump described work on a vaccine for tick‑borne diseases led by a research team that also developed an RSV vaccine; she said the team’s methods produced a major decline in infant hospitalizations for RSV and that the tick research could be transformative, but she committed to provide follow-up details on whether the new vaccine is wholly de novo or derived from an earlier product.

Why it matters: UVM positioned these projects as drivers of workforce training and regional economic development — training students for high‑tech manufacturing and translating biotech discoveries into commercial opportunities for Vermont.

Follow-up and funding status: Trump said the federal grant process had been paused previously and is now being reviewed; she reported the Northeast Microelectronics Coalition funding and encouraged committee members to watch for further news as federal reviews proceed.